Paclitaxel induces significant changes in epidoxorubicin distribution in mice

Annals of Oncology

Volumn 7, Issue 8, 1996, Pages 801-805

  Colombo, T ^a   Gonzalez Paz, O ^a   Zucchetti, M ^a   Maneo, M ^a   Sessa, C ^b   Goldhirsch, A ^b   D'Incalci, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

Epidoxorubicin; Interactions; Paclitaxel; Pharmacokinetics

Indexed keywords

CREMOPHOR; EPIRUBICIN; PACLITAXEL;

ANIMAL EXPERIMENT; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029860377     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010758     Document Type: Article

References (29)

1. Lum BL, Kaubisch S, Yahanda AM et al. Alteration of eto-poside pharmacokinetics and pharmacodynamics by cyclo-sporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635-42.
2. Lum BL, Fisher GA, Brophy NA et al. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmaco-dynamic considerations. Cancer 1993; 72: 3502-14.
3. Rushing DA, Raber SR, Rodvold KA et al. The effects of cyclo-sporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer [see comments]. Cancer 1994; 74: 834-41.
4. Erlichman C, Moore M, Thiessen JJ et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 1993; 53: 4837-42.
5. Bartlett NL, Lum BL, Fisher GA et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994; 12: 835-42.
6. Colombo T, Zucchetti M, D'Incalci M. Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Exp Ther 1994; 269: 22-7.
7. Gonzalez O, Colombo T, De Fusco M et al. Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833, Cancer Chemother Pharmacol 1995; 36: 335-40.
8. Holmes FA, Valero V, Walters RS et al. The M.D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. Monogr Natl Cancer Inst 1993; 15: 161-9.
9. Sledge GWJ. Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: The Eastern Cooperative Oncology Group experience. Semin Oncol 1995; 22: 123-5.
10. Seidman AD. The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res 1995; 1: 247-56.
11. Holmes FA. Combination chemotherapy with Taxol (paclitaxel) in metastatic breast cancer. Ann Oncol 1994; 5 (Suppl 6): S23-S27.
12. Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-99.
13. Fisherman JS, Cowan KH, Noone M et al. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 774-82.
14. Dombernowsky P, Gehl J, Boesgaard M et al. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 1996; 1 (Suppl 1): 13-8.
15. Friche E, Jensen PB, Sehested M et al. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun 1990; 2: 297-303.
16. Chervinsky DS, Brecher ML. Baker RM et al. Reversal of C1300 murine neuroblastoma multidrug resistance by cremophor EL, a solvent for cyclosporin A. Cancer Biother 1993; 8: 67-75.
17. Woodcock DM, Jefferson S, Linsenmeyer ME et al. Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 1990; 50: 4199-203.
18. Webster LK, Cosson EJ, Stokes KH et al. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer 1996; 73: 522-4.
19. Broggini M, Italia C, Colombo T et al. Activity and distribution of i.v. and oral 4-demethoxydaunorubicin in murine experimental tumors. Cancer Treat Rep 1984; 68: 739-47.
20. Solis Recéndez MG, Grossin F, Bichat F et al. Drugs interactions between Taxol (TAX) and Adriamycine (ADR) in mice: Difference of ADR incorporation according to the schedule of administration. Proc Am Assoc Cancer Res 1996; 37: 372.
21. Buzdar AU, Holmes FA, Hortobagyi GN. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. Semin Oncol 1995; 22: 101-4.
22. Amadori D, Frassineti GL, Zoli W et al. A phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer. Semin Oncol 1996; 1 (Suppl 1): 19-23.
23. Rischin D, Millward MJ, Webster LK et al. Phase I study of paclitaxel and epidoxorubicin in advanced cancer. Proc Am Soc Clin Oncol 1996; 15: 480.
24. Conte PF, Michelotti A, Baldini E et al. Epirubicin plus paclitaxel, a highly active combination devoid of significant cardiotoxicity in the treatment of metastatic breast cancer. Proc Am Assoc Cancer Res 1996; 15: 138.
25. Schinkel AH, Smit JJ, van Tellingen O et al. Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502.
26. Schinkel AH, Wagenaar E, van Deemter L et al. Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclo-sporin A. J Clin Invest 1995; 96: 1698-705.
27. Croop JM, Raymond M, Haber D et al. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 1989; 9: 1346-50.
28. Bonadonna G, Gianni L, Santoro A et al. Drugs ten years later: Epidoxorubicin. Ann Oncol 1993; 4: 359-69.
29. Pouma P, Bonoron-Adèle S, Robert J. Evaluation of the cardiotoxicity of anthracyclines associated to taxol with the model of isolated perfused rat heart. Proc Am Assoc Cancer Res 1996; 37: 373.